{"id":34994,"date":"2024-03-19T12:07:10","date_gmt":"2024-03-19T11:07:10","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=34994"},"modified":"2024-03-13T13:46:58","modified_gmt":"2024-03-13T12:46:58","slug":"neuer-therapieansatz-bei-nash-mit-fibrose-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/neuer-therapieansatz-bei-nash-mit-fibrose-cme","title":{"rendered":"Neuer Therapieansatz bei \u201eNASH\u201c mit Fibrose [CME]"},"content":{"rendered":"<p>Die nicht durch Alkohol induzierte Steatohepatitis (NonAlcoholic SteatoHepatitis = NASH), auch unter den Bezeichnungen MASH (Metabolic dysfunction-Associated SteatoHepatitis) sowie MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease bekannt , ist eine progressive, fibrosierende Lebererkrankung, die zu einem erheblichen Organschaden f\u00fchren kann , , . Der Erkrankung wurde fr\u00fcher \u2013 obwohl ein h\u00e4ufiger Befund in der niedergelassenen Praxis [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die nicht durch Alkohol induzierte Steatohepatitis (NonAlcoholic SteatoHepatitis = NASH), auch unter den Bezeichnungen MASH (Metabolic dysfunction-Associated SteatoHepatitis) sowie MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease bekannt , ist eine progressive, fibrosierende Lebererkrankung, die zu einem erheblichen Organschaden f\u00fchren kann , , . Der Erkrankung wurde fr\u00fcher \u2013 obwohl ein h\u00e4ufiger Befund in der niedergelassenen Praxis [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5988,5990,5986,5987,5992,5993,2634,5991,5989,5985],"class_list":["post-34994","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-fettleber","tag-maestro-studien","tag-mash","tag-masld","tag-metabolic-dysfunction-associated-steatohepatitis","tag-metabolic-dysfunction-associated-steatotic-liver-disease","tag-nash","tag-nonalcoholic-steatohepatitis","tag-resmetirom","tag-steatohepatitis"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/34994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=34994"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/34994\/revisions"}],"predecessor-version":[{"id":34995,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/34994\/revisions\/34995"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=34994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=34994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=34994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}